Kisqali Fulvestrant Combo Rejected by NICE for Breast Cancer Treatment in the UK
By GeneOnline staff The guidance document cites highly uncertain clinical and cost-effectiveness estimates as the reason for not recommending the therapy. Background and History Novartis’ Kisqali (ribociclib), is a cyclin-dependent …
Read More